mirikizumab · Omvoh

Monoclonal antibody

Also known as LY3074828

Approvedregulatory verdict

Evidence outlook

Approved: Crohn's Disease, Ulcerative Colitis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (6)
CN
  • Adults with moderate to severe active Crohn's disease and ulcerative colitis (IV and SC forms)
Product first approved 2026news.cn
CA
  • Adults with moderately to severely active Crohn's diseasebiospace.com
  • Moderately to severely active ulcerative colitis in adults with inadequate response, loss of response or intolerance to conventional therapy, a biologic or a JAK inhibitor (Notice of Compliance)newswire.ca
Product first approved 2023
EU
  • Moderately to severely active ulcerative colitis in adults
Product first approved 2023EMA
UK
  • Moderately to severely active ulcerative colitis and Crohn's disease
Product first approved 2023medicines.org.uk
JP
  • Moderately to severely active ulcerative colitis (induction and maintenance) where existing therapy is inadequate; Lilly obtained the approval in March 2023
Product first approved 2023answers.and-pro.jp

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (15)
Crohn's Disease
NCT06937099 · Eli Lilly and Company
2025-06-26 – 2028-05 · Crohn's Disease, Obesity or Overweight
What this study did
NCT05509777 · Eli Lilly and Company
2024-03-13 – 2028-04 · Crohn's Disease
What this study did
NCT04232553 · Eli Lilly and Company
2020-06-22 – 2028-03 · Crohn's Disease
What this study did
Ulcerative Colitis
NCT04844606 · Eli Lilly and Company
2021-05-26 – 2030-12 · Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
What this study did
NCT06937086 · Eli Lilly and Company
2025-06-26 – 2028-04 · Ulcerative Colitis, Obesity or Overweight
What this study did
NCT03519945 · Eli Lilly and Company
2018-07-18 – 2027-12 · Ulcerative Colitis
What this study did
NCT05784246 · Eli Lilly and Company
2023-11-22 – 2026-05-01 · Ulcerative Colitis
What this study did
NCT04469062 · Eli Lilly and Company
2021-04-20 – 2024-06-05 · Ulcerative Colitis
What this study did
Other / comorbidity
NCT03556202 · Eli Lilly and Company
2018-09-03 – 2022-02-07 · Psoriasis
What this study did
Phase 2 (6)
Crohn's Disease
NCT02891226 · Eli Lilly and Company
2016-12-14 – 2021-02-05 · Crohn's Disease
What this study did
Ulcerative Colitis
NCT07186101 · Eli Lilly and Company
2025-11-10 – 2029-03 · Ulcerative Colitis
What this study did
NCT06598943 · Eli Lilly and Company
2024-10-10 – 2027-07 · Ulcerative Colitis, Ulcerative Colitis Chronic
What this study did
NCT04004611 · Eli Lilly and Company
2020-05-18 – 2023-03-15 · Ulcerative Colitis
What this study did
NCT02589665 · Eli Lilly and Company
2015-12-09 – 2019-05-07 · Ulcerative Colitis
What this study did
Other / comorbidity
NCT02899988 · Eli Lilly and Company
2016-09-14 – 2019-05-08 · Plaque Psoriasis
What this study did
Phase 1 (18)
Other / comorbidity
NCT07446101 · Eli Lilly and Company
2026-03-24 – 2027-02 · Healthy
What this study did
NCT06475729 · Eli Lilly and Company
2024-06-24 – 2024-12-27 · Healthy
What this study did
NCT05644353 · Eli Lilly and Company
2022-12-05 – 2023-05-25 · Healthy
What this study did
NCT05515601 · Eli Lilly and Company
2022-08-31 – 2023-02-20 · Healthy
What this study did
NCT05069896 · Eli Lilly and Company
2021-10-05 – 2022-06-22 · Healthy
What this study did
NCT04607733 · Eli Lilly and Company
2020-11-02 – 2021-05-17 · Healthy
What this study did
NCT04548219 · Eli Lilly and Company
2020-09-11 – 2021-01-11 · Healthy
What this study did
NCT04137380 · Eli Lilly and Company
2019-12-04 – 2020-12-11 · Healthy
What this study did
NCT03718884 · Eli Lilly and Company
2018-10-23 – 2019-10-28 · Psoriasis
What this study did
NCT03886948 · Eli Lilly and Company
2019-03-27 – 2019-10-04 · Healthy
What this study did
NCT03748940 · Eli Lilly and Company
2018-10-10 – 2019-06-18 · Healthy
What this study did
NCT03662100 · Eli Lilly and Company
2018-09-06 – 2019-01-25 · Healthy
What this study did
NCT02568423 · Eli Lilly and Company
2015-12-02 – 2018-10-24 · Healthy
What this study did
NCT03456713 · Eli Lilly and Company
2018-03-06 – 2018-08-13 · Healthy
What this study did
NCT03053622 · Eli Lilly and Company
2017-04-24 – 2018-04-03 · Healthy
What this study did
NCT03220126 · Eli Lilly and Company
2017-07-17 – 2018-02-23 · Healthy
What this study did
NCT03188510 · Eli Lilly and Company
2017-06-30 – 2017-11-27 · Healthy
What this study did
NCT01947933 · Eli Lilly and Company
2013-10 – 2015-02 · Psoriasis
What this study did
Phase 4 (10)
Crohn's Disease
NCT07782021 · Icahn School of Medicine at Mount Sinai
2026-12 – 2029-07 · Crohn's Disease, Perianal Fistula
What this study did
NCT07659353 · University Hospital Schleswig-Holstein
2026-08-01 – 2029-03-31 · Chrohn's Disease
What this study did
NCT07292012 · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
2026-05-11 – 2028-11 · Crohn Disease (CD)
What this study did
NCT06997965 · Alimentiv Inc.
2026-04-20 – 2028-04-01 · Crohn Disease
What this study did
Ulcerative Colitis
NCT07235904 · University Hospital Schleswig-Holstein
2025-12-05 – 2028-10 · Ulcerative Colitis (UC)
What this study did
NCT07612267 · Eli Lilly and Company
2026-08-05 – 2028-09 · Lactation, Inflammatory Bowel Disease
What this study did
INSIGHT-IBD Pragmatic Studyenrolling by invitation
NCT07686757 · Specialty Networks Research.
2026-08-12 – 2028-06 · Ulcerative Colitis (UC), Crohn Disease (CD)
What this study did
NCT07059130 · Rubix LS
2025-07-16 – 2026-02-28 · Crohn Disease (CD), Crohns Disease, Ulcerative Colitis (UC)
What this study did
NCT06626165 · Showa Inan General Hospital
2024-07-20 – 2025-09-30 · Ulcerative Colitis
What this study did
Other / comorbidity
NCT06864403 · University of North Carolina, Chapel Hill
2025-08-12 – 2027-10 · Pouchitis, Pouches, Ileoanal, Pouch, Ileal
What this study did
Appears in other studies (2)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (2)
Crohn's Disease
NCT07483099 · Eli Lilly and Company
2026-05-04 – 2028-03 · Crohn Disease
What this study did
Ulcerative Colitis
NCT07483073 · Eli Lilly and Company
2026-05-04 – 2028-03 · Colitis, Ulcerative, Crohn Disease
What this study did

Competitive landscape

This mechanism is crowded: 12 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Ulcerative Colitis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Mirikizumab (Omvoh): this drugApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT03524092: Percentage of Participants in Clinical Remission at Week 40 (Mirikizumab Induction Responders) (Week 40): Maintenance Period: Miri IR - 200 mg Miri SC 49.9% (95% CI 44.7 to 55) vs Maintenance Period: Miri IR - PBO SC 25.1% (95% CI 18.8 to 31.5)
NCT03518086: Percentage of Participants With Clinical Remission at Week 12 (Week 12): Placebo IV Q4W 13.3% (95% CI 6.9-19.6) vs 300 mg Mirikizumab IV Q4W 24.2% (95% CI 19.5-28.9); p=0.00006 (Placebo IV Q4W vs 300 mg Mirikizumab IV Q4W)
Adalimumab (Humira)ApprovedMonoclonal antibodyTNF-alphaPartial signal
NCT00408629: Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8 (Week 8): Adalimumab 160/80/40 16.5% vs Placebo 9.3%; p=0.019 (Adalimumab 160/80/40 vs Placebo)
NCT02065557: Induction (Week 8, ITT-E, Main Study): I-SD 43.3% vs external placebo 19.83% (p=0.382, NS); I-HD 59.6% vs external placebo (p<0.001); combined I-SD+I-HD 53.2% (p<0.001). Maintenance (Week 52, mITT-E): M-PL 33.3% (n=12, descriptive only); M-SD 29.0% vs external placebo 18.37% (p=0.382, NS); M-HD 45.2% (p<0.001); combined M-SD+M-HD 37.1% (p<0.001).
Adalimumab-Aacf (Idacio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aaty (Yuflyma)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adaz (Hyrimoz)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adbm (Cyltezo)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Afzb (Abrilada)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aqvh (Yusimry)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Atto (Amjevita)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Bwwd (Hadlima)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Fkjp (Hulio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Ryvk (Simlandi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Balsalazide Disodium (Colazal)
ApprovedUS marketing discontinued
Small moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Budesonide (Uceris Rectal Foam)ApprovedSmall moleculeGlucocorticoid receptorReliable signalNo reviewed efficacy summary in this indication
Budesonide MMX (Uceris)ApprovedSmall moleculeGlucocorticoid receptorPartial signal
NCT01532648: Registered primary, clinical remission at day 56 (UCDAI rectal bleeding and stool frequency subscores of 0), budesonide MMX 9 mg vs placebo added to oral mesalamine: 56/230 vs 52/228 (CT.gov); similar in both groups, p=0.70 (Rubin 2017). Combined clinical and endoscopic remission at week 8: 13.0% vs 7.5%, p=0.049. missed
DexamethasoneApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Etrasimod (Velsipity)ApprovedSmall moleculeS1P receptorReliable signal
NCT03945188: Percentage of Participants Achieving Clinical Remission at Week 12 (At Week 12): Etrasimod 2 mg 27.0% vs Placebo 7.4%; p=<0.001 (Etrasimod 2 mg vs Placebo)
NCT03996369: Percentage of Participants Achieving Clinical Remission (Week 12): Etrasimod 2 mg 24.8% vs Placebo 15.2%; p==0.026 (Etrasimod 2 mg vs Placebo)
Golimumab (Simponi)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT01863771: Number of Participants Who Achieved Clinical Response Through Maintenance-Week 54 Measured Using the Mayo Score (Up to Week 54): Placebo 6/31 (19.4%) (95% CI 5.4-33.3) vs Golimumab 18/32 (56.3%) (95% CI 39.1-73.4)
NCT00488631: Number of Participants in Clinical Response Through Week 54 (Induction Baseline, Week 0 through Week 54): Golimumab Induction Responders (GLM-I-Rsp)-Placebo Maintenance 48/154 (31.2%) vs GLM-I-Rsp-Golimumab 50 mg Maintenance 71/151 (47.0%) vs GLM-I-Rsp-Golimumab 100 mg Maintenance 75/151 (49.7%); p=0.010 (Golimumab Induction Responders (GLM-I-Rsp)-Placebo Maintenance vs GLM-I-Rsp-Golimumab 50 mg Maintenance), p=<0.001 (Golimumab Induction Responders (GLM-I-Rsp)-Placebo Maintenance vs GLM-I-Rsp-Golimumab 100 mg Maintenance)
Guselkumab (Tremfya)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT05528510: Percentage of Participants in Clinical Remission at Week 12 (Week 12): Placebo 6.5 Percentage of participants (95% CI 2.4 to 10.6) | Combined Guselkumab 400 mg 27.6 Percentage of participants (95% CI 22.4 to 32.8)
QUASAR/GALAXI: superior to ustekinumab on pooled endoscopic endpoints
Hydrocortisone (Cortenema)ApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Hydrocortisone Acetate (Cortifoam)ApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Infliximab (Remicade)ApprovedMonoclonal antibodyTNF-alphaWeak signal
NCT01585155: Percent of Patients Who Achieved CAI Remission (Weeks 2, 6, 8, 10, 14, 18, 22, 26, 30, and the last time point during the period from administration of the study drug to Week 30): TA-650 — Weeks 2: 60%; Weeks 6: 80%; Weeks 8: 80%; Weeks 10: 77.8%; Weeks 14: 87.5%; Weeks 18: 87.5%; Weeks 22: 64.3%; Weeks 26: 85.7%; Weeks 30: 64.3%; The last time point: 42.9%
NCT00336492: The Number of Participants With Clinical Response at Week 8 (Week 8): Infliximab 5 mg/kg 44/60 (73.3%)
Infliximab-Abda (Renflexis)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Axxq (Avsola)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Dyyb (Inflectra)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Dyyb (Zymfentra)ApprovedMonoclonal antibodyTNF-alphaReliable signalNo reviewed efficacy summary in this indication
Infliximab-Qbtx (Ixifi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Mesalamine (Apriso)ApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Mesalamine (Canasa)ApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Mesalamine (Lialda)ApprovedSmall moleculeAminosalicylateReliable signal
NCT00151892: Endoscopic Remission of Ulcerative Colitis (UC) at 6 Months (6 Months): SPD476 83.7 percent of participants | Asacol 81.5 percent of participants
Mesalamine (Pentasa)ApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Mesalamine (Rowasa)ApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
MethylprednisoloneApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Olsalazine (Dipentum)ApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Ozanimod (Zeposia)ApprovedSmall moleculeS1P receptorReliable signal
NCT02435992: Percentage of Participants in Clinical Remission at 10 Weeks (At 10 Weeks): RPC1063 Cohort 1(Induction Period) 18.4% vs Placebo Cohort 1 (Induction Period) 6.0% vs RPC1063 Cohort 2 (Induction Period) 21.0%; p=0.0001 (RPC1063 Cohort 1(Induction Period) vs Placebo Cohort 1 (Induction Period))
NCT03915769: Clinical response at week 12: 52.9% (0.46 mg) and 61.5% (0.92 mg) vs 32.3% placebo.
Risankizumab (Skyrizi)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
INSPIRE/COMMAND: clinical remission + endoscopic improvement met
NCT03398148: Sub-Study 1: Percentage of Participants Achieving Clinical Remission Per Adapted Mayo Score (Week 12): Substudy 1, Induction Period 1: Double-blind Placebo IV 1/60 (1.7%) vs Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV 7/61 (11.5%) vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV 6/61 (9.8%) vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV 6/58 (10.3%) vs Substudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV 42/340 (12.4%); p=0.0324 (Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV), p=0.0460 (Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV), p=0.0397 (Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV)
SulfasalazineApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Tildrakizumab (Ilumya)
Approved(overall)
Monoclonal antibodyIL-23 p19
Reliable signal(overall)
No reviewed efficacy summary in this indication
Tofacitinib (Xeljanz)ApprovedSmall moleculeJAK, JAK1/JAK3Reliable signal
NCT01458574: Percentage of Participants In Remission at Week 52 (Week 52): Tofacitinib 5 mg BID 34.3% vs Tofacitinib 10 mg BID 40.6% vs Placebo 11.1%; p=<0.0001 (Tofacitinib 5 mg BID vs Placebo), p=<0.0001 (Tofacitinib 10 mg BID vs Placebo)
NCT01458951: Percentage of Participants With Remission at Week 8 (Week 8): Tofacitinib 10 mg BID 16.6% vs Placebo BID 3.6%; p=0.0005 (Tofacitinib 10 mg BID vs Placebo BID)
Upadacitinib (Rinvoq)ApprovedSmall moleculeJAK, JAK1Reliable signal
NCT03653026: Percentage of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8 (Week 8): Upadacitinib 45 mg 33.5% (95% CI 28.5-38.5) vs Placebo 4.1% (95% CI 1.1-7.1); p=<0.001 (Upadacitinib 45 mg vs Placebo)
NCT02819635: Substudy 1: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8 (At Week 8): SS1: Placebo 0% vs SS1: Upadacitinib 7.5 mg 8.5% vs SS1: Upadacitinib 15 mg 14.3% vs SS1: Upadacitinib 30 mg 13.5% vs SS1: Upadacitinib 45 mg 21.4%; p=0.049 (SS1: Placebo vs SS1: Upadacitinib 7.5 mg), p=0.010 (SS1: Placebo vs SS1: Upadacitinib 15 mg), p=0.007 (SS1: Placebo vs SS1: Upadacitinib 30 mg), p=<0.001 (SS1: Placebo vs SS1: Upadacitinib 45 mg)
Ustekinumab (Stelara)ApprovedMonoclonal antibodyIL-12 p40Reliable signal
NCT02407236: Induction Study - Number of Participants With Clinical Remission at Week 8 (As Per Global Definition) (Week 8): Induction Study (IS): Placebo Intravenous (IV) 17/319 (5.3%) vs IS: Ustekinumab 130 Milligram (mg) IV 50/320 (15.6%) vs IS: Ustekinumab Approximately 6 mg/kg IV 50/322 (15.5%); p=< 0.001 (Induction Study (IS): Placebo Intravenous (IV) vs IS: Ustekinumab 130 Milligram (mg) IV), p=< 0.001 (Induction Study (IS): Placebo Intravenous (IV) vs IS: Ustekinumab Approximately 6 mg/kg IV)
NCT04630028: Week 8 clinical remission 25% (27/107) after IV induction; the study's primary endpoint is week 52 remission in week 8 responders.
Ustekinumab-Aauz (Otulfi)Approved—IL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Aekn (Selarsdi)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Auub (Wezlana)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Hmny (Starjemza)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Srlf (Imuldosa)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Stba (Steqeyma)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Ttwe (Pyzchiva)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Vedolizumab (Entyvio)ApprovedMonoclonal antibodyα4β7 integrinReliable signal
NCT02497469: Percentage of Participants Who Achieved Clinical Remission (Week 52): Adalimumab SC, 160/80/40 mg 22.5% (95% CI 18.5-27.0) vs Vedolizumab IV 300 mg 31.3% (95% CI 26.7-36.2); p=0.0061 (Adalimumab SC, 160/80/40 mg vs Vedolizumab IV 300 mg)
NCT02611830: Percentage of Participants Achieving Clinical Remission at Week 52 (Week 52): Maintenance Phase: Induction IV + Placebo 14.3% (95% CI 6.4-26.2) vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC 46.2% (95% CI 36.5-56.2) vs Maintenance Phase: Induction IV + Vedolizumab 300 mg IV 42.6% (95% CI 29.2-56.8); p=<0.001 (Maintenance Phase: Induction IV + Placebo vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC)
Mesalamine (Asacol HD)US approval withdrawnSmall moleculeAminosalicylatePartial signalNo reviewed efficacy summary in this indication
AfimkibartPhase 3Monoclonal antibodyTL1APartial signal
NCT04090411: Induction Period: Percentage of Participants Who Achieved Clinical Remission at Week 14 (At Week 14): Induction Period: Placebo 11.6% (95% CI 5.77-22.88) vs Induction Period: PF-06480605 50 mg 25.5% (95% CI 15.44-37.19) vs Induction Period: PF-06480605 150 mg 23.3% (95% CI 14.98-33.98) vs Induction Period: PF-06480605 450 mg 23.9% (95% CI 16.58-32.06); p=0.0545 (Induction Period: Placebo vs Induction Period: PF-06480605 50 mg), p=0.0823 (Induction Period: Placebo vs Induction Period: PF-06480605 150 mg), p=0.0642 (Induction Period: Placebo vs Induction Period: PF-06480605 450 mg) missed
DuvakitugPhase 3Monoclonal antibodyTL1APartial signal
NCT05499130: UC cohort, clinical remission at week 14: 36% (450 mg) / 48% (900 mg) vs 20% placebo, placebo-adjusted 16% (p=.050) / 27% (p=.003). CD cohort, endoscopic response: 26.1% (low dose) / 47.8% (high dose) vs 13.0% placebo. P-values are one-sided at a 0.10 significance level.
HS-20137
Phase 3(overall)
Monoclonal antibodyIL-23 p19
not yet graded(overall)
No reviewed efficacy summary in this indication
Icotrokinra (Icotyde)Phase 3PeptideIL-23 receptorReliable signal
NCT06049017: Primary endpoint clinical response at Week 12: 63.5% with the highest icotrokinra dose vs 27% with placebo (p<0.001)
JNJ-78934804Phase 3CombinationIL-23 p19, TNF-alphanot yet gradedNo reviewed efficacy summary in this indication
MufemilastPhase 3Small moleculePDE4not yet gradedNo reviewed efficacy summary in this indication
ObefazimodPhase 3Small moleculemiR-124Reliable signal
NCT05535946: ABTECT maintenance, clinical remission at Week 44: placebo 10.4% (20), 25 mg 50.8% (98; placebo-adjusted +39.3%), 50 mg 51.3% (100; placebo-adjusted +40.3%), p<0.0001
NCT05507203: ABTECT-1 (NCT05507203), clinical remission at Week 8: placebo 2.5% (4/158), 25 mg 23.8% (38/160, p<0.0001), 50 mg 21.7% (69/318, p<0.0001; placebo-adjusted +19.3%)
PonesimodPhase 3Small moleculeS1P receptornot yet gradedNo reviewed efficacy summary in this indication
QL2106
Phase 3(overall)
Monoclonal antibodyIL-23 p19
not yet graded(overall)
No reviewed efficacy summary in this indication
TulisokibartPhase 3Monoclonal antibodyTL1AReliable signal
NCT06052059: ATLAS-UC Study 2 (NCT06052059): tulisokibart met its primary endpoint of clinical remission (Modified Mayo Score) at week 12, plus key secondary endpoints.
NCT04996797: Remission 26% vs 1% placebo; +25pp (95% CI 14–37)
AC-101Phase 2Small moleculeRIPK2not yet gradedNo reviewed efficacy summary in this indication
ALTB-268Phase 2Monoclonal antibodyPSGL-1Weak signalNo reviewed efficacy summary in this indication
AmiselimodPhase 2Small moleculeS1P receptorReliable signal
NCT04857112: Change from baseline in modified Mayo Score at Day 85: amiselimod -2.3 vs placebo -1.6 (p=0.002)
ATH-063Phase 2Small moleculeG9A (EHMT2)Weak signalFeatured results are safety only in this race
Avrukibart
Phase 2(overall)
Monoclonal antibodyIL-23 p19
Partial signal(overall)
No reviewed efficacy summary in this indication
BI 3032950Phase 2Monoclonal antibodyTREM-1not yet gradedNo reviewed efficacy summary in this indication
CU104Phase 2Small moleculeEndothelial barrier functionPartial signalNo reviewed efficacy summary in this indication
GarutadustatPhase 2Small moleculePHD1/2not yet gradedNo reviewed efficacy summary in this indication
HRS-7085Phase 2Small moleculeNCBP1/NCBP2 (nuclear cap-binding complex)Weak signalNo reviewed efficacy summary in this indication
IPG11406Phase 2Small moleculeEBI2Weak signalFeatured results are safety only in this race
MT-201Phase 2Biologic (subtype unspecified)—not yet gradedNo reviewed efficacy summary in this indication
MT-501Phase 2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
OD-07656Phase 2Small moleculeRIPK2Weak signalNo reviewed efficacy summary in this indication
OmilancorPhase 2Small moleculeLANCL2Partial signal
NCT03861143: Clinical Remission (Week 12): BT-11 Low-dose (440 mg) 30.3% | BT-11 High-dose (880 mg) 31.8% vs Placebo 22.7%
PicankibartPhase 2Monoclonal antibodyIL-23 p19Partial signal
NCT05377580: Week 12 clinical remission (primary endpoint): picankibart 200 mg 20.0% and 600 mg 14.0% vs placebo 2.0% (p<0.05).
SHR-1139Phase 2Monoclonal antibodyIL-23 p19, IL-36 receptornot yet gradedNo reviewed efficacy summary in this indication
SPY003Phase 2Monoclonal antibodyIL-23 p19Partial signal
NCT07012395: Part A primary endpoint (week 12): Robarts Histopathology Index reduced 10.0 points from baseline (p<0.0001) (Spyre, 2026-09-08).
ZotemtegrastPhase 2Small moleculeα4β7 integrinWeak signal
NCT05611671: Percentage of Participants in Clinical Remission as Determined Using the Modified Mayo Clinic Score (mMCS) (Week 12): MORF-057 200 mg BID 31.9% | MORF-057 100 mg BID 23.9% | MORF-057 100 mg QD-M 17.1% vs Placebo 24.3% missed
NCT05291689: Main Cohort: Change From Baseline to Week 12 in the Robarts Histopathology Index (RHI) Score (From baseline to 12 weeks): MORF-057 (Main Cohort) -6.4 score on a scale (Standard Deviation 11.18)
ICG318Phase 1/2Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
Remestemcel-L (Ryoncil)Phase 1/2Cell therapyAllogeneic MSC therapynot yet gradedNo reviewed efficacy summary in this indication
BDHK-2009Phase 1Small molecule—not yet gradedNo reviewed efficacy summary in this indication
ExoFloPhase 1Cell therapyMSC-derived exosomesWeak signalNo reviewed efficacy summary in this indication
LMT503Phase 1Small moleculeMacrophage polarization / Cellular metabolismnot yet gradedNo reviewed efficacy summary in this indication
SOR102Phase 1Biologic (subtype unspecified)TNF-alpha, IL-23 p19Weak signalFeatured results are safety only in this race
TL-003Phase 1Multispecific antibodyTL1A, IL-23 p19not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 84 furthest-along competitors are listed; 34 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(14 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Omvoh (mirikizumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (6)
February 2027 (1)
Phase 1HealthyRecruiting
Est. primary completion 2027-02 · NCT07446101 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2Ulcerative ColitisRecruiting
Est. primary completion 2027-05 · NCT07186101 · CT.gov ↗
What to watch
September 2027 (1)
Phase 4Crohn's DiseaseRecruiting
Est. primary completion 2027-09-01 · NCT06997965 · CT.gov ↗
What to watch
October 2027 (1)
Phase 4Pouchitis, Pouches, Ileoanal, Pouch, IlealActive not recruiting
Est. primary completion 2027-10 · NCT06864403 · CT.gov ↗
What to watch
November 2027 (1)
Phase 4Crohn's DiseaseRecruiting
Est. primary completion 2027-11 · NCT07292012 · CT.gov ↗
What to watch
December 2027 (1)
Phase 3Crohn's DiseaseRecruiting
Est. primary completion 2027-12 · NCT05509777 · CT.gov ↗
What to watch
2028 (6)
March 2028 (1)
Phase 4Ulcerative ColitisRecruiting
Est. primary completion 2028-03 · NCT07235904 · CT.gov ↗
What to watch
April 2028 (1)
Phase 3Ulcerative ColitisRecruiting
Est. primary completion 2028-04 · NCT06937086 · CT.gov ↗
What to watch
May 2028 (1)
Phase 3Crohn's DiseaseRecruiting
Est. primary completion 2028-05 · NCT06937099 · CT.gov ↗
What to watch
June 2028 (1)
Phase 4Crohn's DiseaseEnrolling by invitation
Est. primary completion 2028-06 · NCT07686757 · CT.gov ↗
What to watch
September 2028 (1)
Phase 4Crohn's DiseaseRecruiting
Est. primary completion 2028-09 · NCT07612267 · CT.gov ↗
What to watch
December 2028 (1)
Phase 4Crohn's DiseaseNot yet recruiting
Est. primary completion 2028-12 · NCT07782021 · CT.gov ↗
What to watch
2029 (1)
March 2029 (1)
Phase 4Crohn's DiseaseNot yet recruiting
Est. primary completion 2029-03-31 · NCT07659353 · CT.gov ↗
What to watch
2030 (1)
December 2030 (1)
Phase 3Crohn's DiseaseRecruiting
Est. primary completion 2030-12 · NCT04844606 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

19 October 2026Topline resultPhase 3 SHINE-2 of Omvoh met its primary endpoint in pediatric UC
27 October 2025PresentationLUCENT-URGE Phase 3b bowel urgency results
Eli Lilly · Source ↗
27 October 2025ApprovalFDA approves Omvoh single-injection maintenance regimen for UC
US, FDA · Source ↗
15 January 2025ApprovalFDA approves Omvoh for Crohn's disease
US, FDA · Source ↗